BioSpace News Archive

Sickle Cell warrior Tahir “StayFresh” Ali of Atlanta, Ga., visits the hospital twice monthly for blood transfusions to reduce complications from sickle cell disease, and manage his potential risk of organ damage or stroke.

Havn Life Sciences Inc., is pleased to announce that it has successfully completed its acquisition of HAVN Research Inc., acquiring 100% of the outstanding shares of HAVN Research.

Humanigen, Inc., a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with lenzilumab, the company’s proprietary Humaneered® anti-human granulocyte macrophage-colony stimulating factor monoclonal antibody, announced that its board of directors has determined to effect a 1-for-5 reverse split of its outstanding shares of common stock.

Humanigen, Inc. announced that its board of directors has determined to effect a 1-for-5 reverse split of its outstanding shares of common stock.

DENTSPLY SIRONA Inc. (“Dentsply Sirona”) (Nasdaq: XRAY), the Dental Solutions Company, today announced that it will participate in the Baird 2020 Global Healthcare Conference on September 10 th . Jorge Gomez, Chief Financial Officer, will represent the company and is scheduled to participate in a fireside chat at 10:50 AM Eastern Daylight Time. Investors and other interested parties will be able to access a live audio webcast of the presen

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced that the Company’s Compensation Committee granted 105 new employees non-qualified stock options to purchase an aggregate of 530,000 common shares, at a per share exercise price of $14.83

– Gavreto is a once-daily, oral precision therapy that selectively inhibits RET-altered cancers – – Genentech and Blueprint Medicines will co-commercialize Gavreto in the United States – – FDA also granted Priority Review to Gavreto for the treatment of people with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer – SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )-- Genentech, a member

Columbia Care Inc. is scheduled to participate in the following virtual investor conferences in September:

Syntekabio, an AI and NGS-based drug development company, announced that their COVID-19 combination therapy candidates yielded lung pathogenicity recovery rate of 94.3%, while the Remdesivir showed recovery rate of 44.3%.

Two-week programme to spark first pan-global debate on pharma’s 2020 transformations underway. Sessions will cover affordable medicines, ultra-rapid innovation, supply change resiliency, AI, Vaccine production, COVID -19, CDMO M&A, health-tech cross industry collaboration and many more.